Background: Several parameters including inflammatory mediators, hormones, dietary factors, inflammatory genes, and oxidative stress (OS) have been considered to play a role in the development of benign prostatic hyperplasia (BPH). Prostate tissue damage and OS may lead to compensatory cellular proliferation with resulting hyperplastic growth. Methods: We searched MEDLINE for articles in English published up to March 2014 using the key words ‘oxidative stress', ‘antioxidants' and ‘benign prostatic hyperplasia'. Results: Prostatic inflammation can cause the generation of free radicals. The extent of oxidative damage can be exacerbated by a decreased efficiency of antioxidant defense mechanisms. The balance between OS and the antioxidant component also has a role in developing prostate disease. Several works show the role of oxidant products and of depletion of antioxidant substances in BPH patients. It is accepted that free radicals play a role in carcinogenesis and that BPH should be considered a premalignant condition which may evolve into prostate cancer. High OS parameters and low antioxidant activity are more prominent in prostate cancer patients compared with BPH and controls. Conclusions: Further studies are needed to clarify the potential role of antioxidants in BPH also in view of preventing the progression to prostate cancer.

Benign prostatic hyperplasia (BPH) is a prevalent and chronic progressive disease that may be correctly defined as prostate gland enlargement secondary to hyperproliferation of stromal and glandular cells, with predominance of mesenchymal cells [1]. It is an extremely common disease of ageing men and carries a distressingly high morbidity because of its irritative and obstructive symptoms. The etiology and pathogenesis of BPH are not well understood [2].

Several parameters including inflammatory mediators, hormones, dietary factors, inflammatory genes, and oxidative stress (OS) have been considered to play a role in the development of BPH, but there is no consensus as to which is the primary one. To date, these multifactorial and chronic conditions have been studied to prevent BPH progression. In the last few years, a relationship between prostatic inflammation and lower urinary tract symptoms related to BPH has been suggested [3]. Today, even though it is not yet known exactly when and why chronic inflammation occurs, it has been hypothesized that BPH is an immune-mediated inflammatory disease and inflammation may directly contribute to prostate growth [3].

OS is an imbalance between the production and detoxification of reactive oxygen species (ROS) that can cause tissue damage. Leukocytes are the major source of ROS, and in the case of inflammation, the production of ROS is very much elevated and can exhaust the anti-oxidative protection system [4]. Therefore, OS can result from either an excess in oxidant production or depletion of antioxidant defenses.

We present a comprehensive collection of up-to-date systematic reviews and other important publications on the complex association of OS and BPH. We describe important developments and perspectives based on a systematic analysis of the most cited research in this field.

We searched MEDLINE for articles in English published up to March 2014 using the key words ‘oxidative stress', ‘antioxidants' and ‘benign prostatic hyperplasia'. All the studies showing data about the measurement of OS in BPH were included.

Role of Oxidant Production (table 1)

Prostate tissue damage and OS may lead to compensatory cellular proliferation with the resulting hyperplastic growth. Prostatic inflammation can cause the generation of free radicals/OS such as inducible nitric oxide (iNOS), reactive nitric species and ROS [5]. Both macrophages and neutrophils provide a source of free radicals that can induce hyperplastic transformations through OS to tissue and DNA [6].

Table 1

Summary of considered studies

Summary of considered studies
Summary of considered studies

OS can induce vascular tissue damage, protein structure and function damage, genomic damage and cause posttranslational modifications including those involved in DNA repair and apoptosis [7]. These can lead to oxidative DNA damage in point mutations, deletions, or rearrangements and reduce DNA repair. OS also alters the stem cell population. Genomic alterations in cellular DNA result in the modulation of an imbalance between cell proliferation and cell death. A change in the normal regulation of programmed cell death leads to hyperplastic or precancerous transformation [5].

Human prostate tissue is vulnerable to oxidative DNA damage due to more rapid cell turnover and fewer DNA repair enzymes. OS then can activate the transcription factor NF-κB by the TNF-α/AP-1 transduction pathway and the NF-κB-inducing kinase (NIK) transduction pathway. NF-κB is known as a master inflammatory transcriptional regulator; its targets include genes regulating immune response, inflammation, cell proliferation, cell migration, and apoptosis. The nuclear translocation of NF-κB can activate target genes involved in carcinogenesis. Dysregulation of NF-κB has been proposed to be one putative molecular mechanism leading to chronic inflammation and cancer [5]. Exposure of prostate epithelial cells to proinflammatory soluble mediators directly activates NF-κB and induces local production of proinflammatory cytokines in the prostate epithelial cells [8].

In normal prostate, the transduction pathway from NIK to NF-κB seems to be inactive. In BPH, there was increasing TNF-α/AP-1 transduction pathway also followed by increasing apoptotic pathway to inhibit uncontrolled cell proliferation [5]. Another study demonstrated a novel link between OS and loss of imprinting, showing that OS, measured by increased NF-κB activity, induces loss of imprinting of insulin-like growth factor 2 in both cancerous and noncancerous human prostate cells. This loss during aging is important in tumorigenesis. Therefore, modulating NF-κB may prevent age-related alteration in the epigenome [9].

In all the inflammatory cells that arrive in the prostate, iNOS activates reactive nitrogen that can damage cells [10]. iNOS is not detected in normal prostate, while it is expressed in the prostate of all BPH patients, even in the absence of prostatitis or systemic signs of an inflammatory condition. This suggests that sex hormones may be involved in iNOS induction and that there may be a role for NO in the pathogenesis of BPH [11].

NO and cyclooxygenase (COX) activity may play an important role in determining the association between inflammation and prostate growth. Inflammatory cells that are present in the prostate and iNOS are the principal factors activating reactive nitrogens that can damage cells. NOS expression in human prostate tissue has been characterized by increased immunostaining in the epithelial cells of cases with BPH when compared with normal tissue [12]. NO also enhances COX activity. COX-2 activity has been detected in all inflammatory cells in the epithelium and interstitial spaces of human prostate tissue, and it is increased in proliferative inflammatory lesions, generating proinflammatory prostaglandins [13,14]. Moreover, COX-2 has shown to upregulate Bcl-2 expression with an associated decrease in apoptosis in prostate tissue [15]. Moreover, COX-2 inhibition has been shown to induce prostate cell apoptotic activity [16].

Another nitrosative stress-related parameter, plasma nitrite/nitrate, was found elevated in BPH patients compared with controls [17].

ROS may also indirectly cause the formation of DNA adducts by initiating autocatalytic lipid peroxidation, which generates a large variety of potential genotoxic breakdown products, including alkoxyl radicals, peroxyl radicals, and aldehydes, such as malondialdehyde (MDA) [18,19].

High plasma peroxide levels were found in BPH patients compared with controls [20].

Lipid peroxidation, estimated by measurement of thiobarbituric acid reactive substances was found to be increased in BPH patients compared with controls [21,22].

MDA is an end product derived from peroxidation of polyunsaturated fatty acids and related esters. In contrast to free radicals, aldehydes are relatively stable and therefore able to diffuse within or out of the cell and to attack targets distant from the site of original free radical-initiated events. Furthermore, MDA does not just reflect lipid peroxidation, but is also a by-product of cyclooxygenase activity in platelets, and persistent platelet activation is a common feature of many clinical syndromes associated with enhanced lipid peroxidation. Thus, measurement of MDA levels in plasma or serum provides a convenient in vivo index of lipid peroxidation and represents a noninvasive biomarker of OS often clinically employed to investigate radical-mediated physiological and pathological conditions [19].

Circulating MDA levels were found to be significantly higher in BPH patients than in healthy donors [17,23,24,25] and strongly correlated with prostate-specific antigen levels [23]. However, other works found circulating MDA levels in BPH patients similar to those in controls [26].

Lipid peroxidation can also trigger prostaglandin synthesis via activating COX-2 [14].

Another product of lipid peroxidation, 8-epi-prostaglandin F2α (8-EPI), is an isoprostane produced by the nonenzymatic peroxidation of arachidonic acid by ROS. In urine, it is a reliable approach to assess systemic OS in vivo [27]. 8-EPI urinary levels were found elevated in BPH patients in comparison with controls [4]. However, other studies found no significant changes in total oxidative status [28], lipid peroxidation or NOX2 expression [29] in BPH patients compared to controls [30].

Role of Depletion of Antioxidant Activity

Normally, highly oxidative stresses are removed by natural protective mechanism, the superoxide dismutase (SOD) enzyme system, such as SOD, glutathione peroxidase (GPX) and catalase (CAT) enzyme, as well as vitaminic antioxidants like α-tocopherol and ascorbate.

The extent of ROS-induced oxidative damage can be exacerbated by a decreased efficiency of antioxidant defense mechanisms. Balance between OS and the antioxidant component of the cells has also a role in developing prostate disease [31]. There are increases in OS and decreased antioxidant mechanisms in prostate diseases reported in several studies; however, the data are not univocal.

Lower activity of SOD and CAT and increased endogenous levels of DNA base products were found in the majority of BPH tissues compared to the surrounding disease-free prostate tissue [32]. Moreover, when both CAT and SOD had decreased activity in BPH tissues than in normal tissues, the increase in DNA base products was more prominent. When only SOD activity was decreased in BPH tissues and CAT activity was similar in both tissues types, the increase in levels of DNA base products was less pronounced. In the case of similar SOD and CAT activity in both tissues types, no changes in levels of DNA products were observed. Therefore, these results suggested a possible association between antioxidant enzyme activity and levels of DNA base lesions in BPH tissues [32].

Decreased total equivalent antioxidant capacity levels were found in patients affected by BPH compared with controls, and an inverse correlation between plasma peroxides and total equivalent antioxidant capacity was observed in those patients. However, no statistically significant modifications were observed as concerns SOD activity [20].

Glutathione S-transferases (GSTs) are a family of phase II xenobiotic metabolizing enzymes, protecting the body from oxidative insults by conjugating glutathione (GSH) with various electrophilic compounds generated after activation by phase I enzymes [33]. Deletion of GSTM1 and GSTT1 genes, which are important isoenzymes of GST, leads to a complete lack of activity of their enzymes. Absence of these enzymes due to homozygous deletions is implicated in poor elimination of carcinogenic substances, making individuals with these deletions susceptible to oxidative injury [34]. A study has reported a positive association of GSTM1 or GSTT1 polymorphism with increased risk of BPH [35]. In individuals with BPH and with double deletions GSTM1-/GSTT1-, significantly higher MDA levels were observed compared to GSTM1+/GSTT1+[34]. Significantly higher MDA levels were also present in BPH subjects amongst GSTM1-/GSTT1+ groups compared to GSTM1+/GSTT1+ genotypes. A study reported the GSTM1 null genotype to be associated with increased risk of BPH [33]. Therefore, the presence of the GSTT1 genotype and/or absence of the GSTM1 genotype might have significance in the possible development of OS in BPH patients [36].

Lower activities of SOD [17,21], GPX [17,23] and reduced GSH concentration [24] versus corresponding controls have been shown in BPH patients; however, one of these studies [17] reported different results between patients from Macedonia and Turkey, the latter showing a decreased activity only in GPX.

The study of Srivastava and Mittal [24] also showed higher GST activity in BPH patients, and a positive correlation between serum MDA level and GSH, GST and GPX in BPH patients. This suggested a cause-and-effect relationship, i.e. if OS developed, an increase in the level of antioxidant would try to nullify the effect [24].

Selenium (Se) is a key component of GPX; it not only increases the activity and/or concentration of GPX, but also the concentration of selenoproteins [37]. Se concentration in whole blood and plasma and red cell GPX activity of BPH patients were lower compared with controls [38]. In another work, the risk of BPH was found significantly decreased with an increased serum Se concentration. However, no significant association between serum selenoprotein P concentration or GPX activity and risk of BPH was found [37].

α-Tocopherol and ascorbate act in synergy in the membrane and cytosol of the cell. α-Tocopherol scavenges lipid peroxy free radicals and interrupts the chain reaction of lipid peroxidation becoming oxidized itself in the process. Ascorbate present in the aqueous compartments acts as a water-soluble chain-breaking antioxidant, converts the tocopheroxyl radical back to active α-tocopherol, thereby replenishing antioxidant activity of α-tocopherol [39]. Decreased levels of α-tocopherol and ascorbate were found in BPH patients; moreover, a significant inverse correlation between ascorbate and MDA was found, but the correlation between α-tocopherol and MDA was not statistically significant [25].

Other studies found no significant difference in total antioxidant capacity between BPH patients and controls [29].

Several studies demonstrated the presence of OS in BPH. OS can be due to an overproduction of oxidant molecules or to a deficiency in the antioxidant system, or both. In BPH, both mechanisms are present.

Growing evidence indicates that the cumulative production of ROS and reactive nitric species through either endogenous or exogenous insults plays a major role in the aging process and age-related diseases.

It is generally accepted that free radicals play a role in the early phases of carcinogenesis and that prostate hyperplasia should be considered a sort of premalignant condition which may evolve into prostate cancer, even though experimental and clinical lines of evidence are still controversial in relation to this last suggestion [20].

Data from the literature show that high OS parameters and low antioxidant activity are more prominent in prostate cancer patients compared with BPH and controls [17,20,21]. Whether the presence of OS-related parameters could be used to make differential diagnosis or to predict prognosis in patients with prostate cancer and BPH is a question which requires further, larger studies for a better management of disease in such patients. Moreover, prospective studies and well-structured research are obviously needed to better clarify the potential role of antioxidants in BPH also in view of preventing the progression to prostate cancer.

1.
Djavan B, Margreiter M, Dianat SS: An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol 2011;21:5-12.
2.
Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S: Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. Indian J Clin Biochem 2012;27:385-388.
3.
Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B: Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5-10.
4.
Kullisaar T, Türk S, Punab M, Mändar R: Oxidative stress - cause or consequence of male genital tract disorders? Prostate 2012;72:977-983.
5.
Hamid AR, Umbas R, Mochtar CA: Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Med Indones 2011;43:59-65.
6.
Chughtai B, Lee R, Te A, Kaplan S: Role of inflammation in benign prostatic hyperplasia. Rev Urol 2011;13:147-150.
7.
Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, et al: Prostate growth and inflammation. J Steroid Biochem Mol Biol 2008;108:254-260.
8.
Wong CP, Bray TM, Ho E: Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett 2009;276:38-46.
9.
Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, et al: A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS One 2014;9:e88052.
10.
Baltaci S, Orhan D, Cogus C, Turkolmez K, Tulunay O, Gogus O: Inducible nitric oxide synthase expression in BPH, low and high grade PIN and prostate carcinoma. BJU Int 2001;88:100-103.
11.
Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, et al: Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999;189:224-229.
12.
Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004;61:60-72.
13.
Palapattu GS, Sutcliffe S, Bastain PJ, Platz EA: Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2004;26:1170-1181.
14.
Sugar LM: Inflammation and prostate cancer. Can J Urol 2006;13(suppl 1):46-47.
15.
Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
16.
Di Silverio F, Bosman C, Salvatori M, Albanesi L, Proietti, Pannunzi L, et al: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005;47:72-78.
17.
Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, et al: Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 2009;42:1228-1235.
18.
Dotan Y, Lichtenberg D, Pinchuk I: Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004;43:200-207.
19.
Meagher EA, FitzGerald GA: Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000;28:1745-1750.
20.
Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al: Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int 2010;85:328-333.
21.
Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, et al: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006;39:176-179.
22.
Goswami K, Nandeesha H, Koner BC, Nandakumar DN: A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis. Prostate Cancer Prostatic Dis 2007;10:356-359.
23.
Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, et al: Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators Inflamm 2003; 12:127-128.
24.
Srivastava DS, Mittal RD: Free radical injury and antioxidant status in patients with benign prostate hyperplasia and prostate cancer. Indian J Clin Biochem 2005;20:162-165.
25.
Aryal M, Pandeya A, Das BK, Lamsal M, Majhi S, Pandit R, et al: Oxidative stress in patients with benign prostate hyperplasia. J Nepal Med Assoc 2007;46:103-106.
26.
Almushatat AS, Talwar D, McArdle PA, Williamson C, Sattar N, O'Reilly DS, et al: Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. Int J Cancer 2006;118:1051-1053.
27.
Montuschi P, Barnes P, Roberts LJ II: Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007;14:703-717.
28.
Savas M, Verit A, Ciftci H, Yeni E, Aktan E, Topal U, et al: Oxidative stress in BPH. J Nepal Med Assoc 2009;48:41-45.
29.
Jones KJ, Chetram MA, Bethea DA, Bryant LK, Odero-Marah V, Hinton CV: Cysteine (C)-X-C receptor 4 regulates NADPH oxidase-2 during oxidative stress in prostate cancer cells. Cancer Microenviron 2013, Epub ahead of print.
30.
Doğru-Abbasoğlu S, Aykaç-Toker G, Koçak T, Unlüer E, Uysal M: Antioxidant enzyme activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. J Cancer Res Clin Oncol 1999;125:402-404.
31.
Khandrika L, Kumar B, Koul S, Marone P, Koul HK: Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-136.
32.
Olinski R, Zastawny TH, Foksinski M, Barecki A, Dizdaroglu M: DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic Biol Med 1995;18:807-813.
33.
Ntais C, Polycarpou A, Ioannidis JP: Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:176-181.
34.
Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-743.
35.
Mittal RD, Kesarwani P, Singh R, Ahirwar D, Mandhani A: GSTM1, GSTM3 and GSTT1 gene variants and risk of benign prostate hyperplasia in North India. Dis Markers 2009;26:85-91.
36.
Kumar V, Yadav CS, Datta SK, Singh S, Ahmed RS, Goel S, et al: Association of GSTM1 and GSTT1 polymorphism with lipid peroxidation in benign prostate hyperplasia and prostate cancer: a pilot study. Dis Markers 2011;30:163-169.
37.
Eichholzer M, Steinbrecher A, Kaaks R, Teucher B, Linseisen J, Rohrmann S: Effects of selenium status, dietary glucosinolate intake and serum glutathione S-transferase α activity on the risk of benign prostatic hyperplasia. BJU Int 2012;110:E879-E885.
38.
Zachara BA, Szewczyk-Golec K, Tyloch J, Wolski Z, Szylberg T, Stepien S, et al: Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia. Neoplasma 2005;52:248-254.
39.
Winkler BS, Orselli SM, Rex TS: The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med 1994;17:333-349.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.